Abbott Laboratories (ABT)
BMV
1,760.00
-6.00 (-0.34%)
Closed
Oct 7, 2026
Day's Range
1,760.001,760.00
52 wk Range
1,413.002,451.00
Financial Statements - ABT - Abbott Laboratories
Revenue
44.32B▼ 94.0%
Net Income
6.52B▼ 97.2%Net Margin 14.7%
EBITDA
12.02B▼ 93.6%
Free Cash Flow
7.39B▼ 93.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 44.32B | 735.74B | 40.10B | 43.65B | 43.07B | 34.60B |
| Cost of Goods | 19.31B | 328.07B | 17.97B | 19.14B | 18.53B | 15B |
| Gross Profit | 25B | 407.66B | 22.13B | 24.51B | 24.53B | 19.60B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 8.05B | 119.70B | 6.47B | 8.36B | 8.42B | 5.35B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 598M | 7.06B | 438M | 319M | 276M | 111M |
| Pre Tax Income | 8.46B | 122.99B | 6.66B | 8.30B | 8.21B | 4.96B |
| Income Tax | 1.94B | -112.05B | 941M | 1.37B | 1.14B | 497M |
| Net Income | 6.52B | 235.05B | 5.72B | 6.93B | 7.07B | 4.49B |
| EPS Basic | 3.756767 | 7.739225 | 3.300316 | 3.989538 | 4.008317 | 2.537784 |
| EPS Diluted | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.5 |
| Basic Shares Outstanding | 1.73B | 30.37B | 85.15M | 85.09M | 86.38M | 86.73M |
| Diluted Shares Outstanding | 1.73B | 30.37B | 85.15M | 85.09M | 86.38M | 86.73M |
| Ebit | 8.95B | 132.80B | 7.30B | 8.86B | 8.74B | 5.51B |
| Ebitda | 12.02B | 188.76B | 10.58B | 12.13B | 12.28B | 8.83B |
| Net Income Continuous Operations | 6.52B | 235.05B | 5.72B | 6.93B | 7.07B | 4.49B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
